Partnering with Yisheng

学术论文

学术论文

Anti-cancer efficacy of systemic and intratumoral YS-ON-001 as monotherapy or in combination with checkpoint inhibitor in syngeneic cancer models. To be presented at AACR 2019, Atlanta, US.


  • A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen. Vaccine. .
    View

  • Proposed revision of the policy on rabies vaccines and rabies immunoglobulins. SAGE Working Group on rabies vaccines and immunoglobulins and the World Health Organization (WHO) Secretariat. .
    View

  • An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers. Vaccine. .
    View

  • A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies. Virology. .
    View

  • Ineffectiveness of rabies vaccination alone for post-exposure protection against rabies infection in animal models. Antiviral Research. 135 (2016), pp. 56-61, .
    View

  • Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice. Vaccine. 32 (2014), pp. 5375-5378, .
    View

  • Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology. .
    View

  • A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine. .
    View